Skip to main content

Aeglea Biotherapeutics, Inc. (AGLE)

NASDAQ: AGLE · IEX Real-Time Price · USD
7.47 0.38 (5.36%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap366.51M
Revenue (ttm)13.70M
Net Income (ttm)-65.80M
Shares Out49.06M
EPS (ttm)-1.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume438,010
Open7.13
Previous Close7.09
Day's Range6.91 - 7.51
52-Week Range5.82 - 9.90
Beta1.67
AnalystsBuy
Price Target14.50 (+94.1%)
Est. Earnings DateNov 4, 2021

About AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeli...

IndustryBiotechnology
IPO DateApr 7, 2016
Employees91
Stock ExchangeNASDAQ
Ticker SymbolAGLE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 14.50, which is an increase of 94.11% from the latest price.

Price Target
$14.50
(94.11% upside)
Analyst Consensus: Buy

News

Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021

AUSTIN, Texas, Sept. 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...

2 weeks ago - PRNewsWire

Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 47.37% and 112.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

1 month ago - PRNewsWire

Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel

AUSTIN, Texas, July 15, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

2 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzi...

AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

2 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer

AUSTIN, Texas, July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

2 months ago - PRNewsWire

Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Trea...

AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

2 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors

AUSTIN, Texas, June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

2 months ago - PRNewsWire

Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

4 months ago - PRNewsWire

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of...

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people w...

4 months ago - PRNewsWire

Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginas...

AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

4 months ago - PRNewsWire

Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021

AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...

5 months ago - PRNewsWire

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Argi...

AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

5 months ago - PRNewsWire

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

6 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors

AUSTIN, Texas, Feb. 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

6 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Transition of Chief Financial Officer

AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

7 months ago - PRNewsWire

Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas, Jan. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people ...

8 months ago - PRNewsWire

Aeglea (AGLE) Upgraded to Buy: Here's Why

Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

8 months ago - Zacks Investment Research

Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors

AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

9 months ago - PRNewsWire

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

9 months ago - PRNewsWire

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference

AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

9 months ago - PRNewsWire

Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences

AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

10 months ago - PRNewsWire

Is a Surprise Coming for Aeglea (AGLE) This Earnings Season?

Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

10 months ago - Zacks Investment Research

Steven Cohen Jumps Back Into Aeglea BioTherapeutics

Billionaire investor Steven Cohen (Trades, Portfolio) revealed a new stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) late last week.

10 months ago - GuruFocus

Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria

AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

10 months ago - PRNewsWire